

Name of Journal: *World Journal of Transplantation*

Manuscript NO: 56893

Manuscript Type: OPINION REVIEW

Lenvatinib as first-line for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients?

Piñero F *et al.* Lenvatinib in recurrent HCC

Federico Piñero, Marcos Thompson, Juan Ignacio Marín, Marcelo Silva

Match Overview

1	Internet 115 words crawled on 07-Aug-2020 www.elsevier.es	4%
2	Crossref 30 words Federico Piñero, Mario Tanno, Gabriel Aballay Soterias, Matías Tisi Baña et al. "Argentinian clinical practice guideline for sur ...	1%
3	Internet 21 words crawled on 14-May-2018 www.oncotarget.com	1%
4	Internet 13 words crawled on 19-Nov-2017 link.springer.com	<1%
5	Internet 12 words crawled on 03-Jun-2017 linknovate.com	<1%
6	Internet 12 words crawled on 29-Apr-2019 jamanetwork.com	<1%



国内版

国际版

Chat with Bing

Lenvatinib as first-line for recurrent HCC after liver transp



Sign in



ALL

IMAGES

VIDEOS

27,000 Results

Any time

Phase I Trial of Sorafenib Following Liver Transplantation ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439789>

Subjects. Post-liver-transplant **HCC patients** aged 18 years or older with histologically confirmed **HCC** on explant were recruited. Subjects were defined as “high risk” **for recurrence** by being outside the Milan criteria either by radiologic criteria before **transplant** or pathologic criteria in the explant, by having tumors with vascular invasion, or by having poorly differentiated tumor histology.

Cited by: 7

Author: Abby B. Siegel, Anthony B. El-Khoueiry, ...

Publish Year: 2015

Locoregional Therapy and Recurrent Hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777313>

Kaplan-Meier analysis of hepatocellular carcinoma (**HCC**) **recurrence after** orthotopic liver **transplantation**. (A) The survival rate was significantly decreased in **patients with HCC recurrence**. (B–F) **Recurrence** risks were stratified by locoregional therapies and tumor necrosis. Log Rank Test, $p < 0.05$ was considered as significant.

Cited by: 9

Author: Min Xu, MB Majella Doyle, Babak Banan, ...

Publish Year: 2017

Search Tools

Turn off Hover Translation (关闭取词)

Lenvatinib as first-line for recurrent hepatocellular carcinoma after li



ALL

IMAGES

VIDEOS

24,000 Results

Any time ▾

Adaptive Zoom



[Hepatocellular Carcinoma Recurrence After Liver ...](#)

<https://www.cancernetwork.com/article/...> ▾

Mar 19, 2020 · Chok KSH. Management of **Recurrent hepatocellular carcinoma after liver transplant**. World J Hepatol. 2015;7(8):1142-1148. doi: 10.4254/wjh.v7.i8.1142. 31. Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of **recurrent hepatocellular carcinoma after liver transplantation**: a case report.

Author: Alejandro Gabutti, Sherrie Bhoori, T... **Publish Year:** 2020

[Targeted therapy for hepatocellular carcinoma | Signal ...](#)

<https://www.nature.com/articles/s41392-020-00264-x>

Aug 11, 2020 · Iavarone, M. et al. Preliminary experience on safety of regorafenib **after** sorafenib failure in **recurrent hepatocellular carcinoma after liver transplantation**. Am. J. Transplant...

Author: Ao Huang, Xin-Rong Yang, Wen-Yu... **Publish Year:** 2020

[A global view of hepatocellular carcinoma: trends, risk ...](#)

<https://www.nature.com/articles/s41575-019-0186-y>

Aug 22, 2019 · Kudo, M. et al. **Lenvatinib** versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase 3 non-inferiority trial. Lancet 391 , 1163–1173 (2018).

Cited by: 193 **Author:** Ju Dong Yang, Pierre Hainaut, Gregory ...

Publish Year: 2019

[Systemic therapies for hepatocellular carcinoma: a recap ...](#)

<https://hrjournal.net/article/view/2501> ▾

Lenvatinib versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase III non-inferiority trial. Lancet 2018;391:1163-73. DOI: 56. Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy



61,100 Results Any time ▾

Hepatocellular Carcinoma Recurrence After Liver ...

<https://www.cancernetwork.com/view/hepatocellular...> ▾

Mar 19, 2020 · Chok KSH. Management of **Recurrent hepatocellular carcinoma after liver transplant**. World J Hepatol. 2015;7(8):1142-1148. doi: 10.4254/wjh.v7.i8.1142. 31. Rivera L, Giap H, Miller W, et al. Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of **recurrent hepatocellular carcinoma after liver transplantation**: a case report.

Impact of treatment modalities on patients with recurrent ...

<https://www.sciencedirect.com/science/article/pii/S1499387220301168>

Aug 01, 2020 · Introduction. **Hepatocellular carcinoma** (HCC) is the sixth most common **cancer** worldwide and the fourth major cause of **cancer**-related death .Because of the high prevalence of hepatitis B virus (HBV) infection and **liver** cirrhosis, 55% of the new cases and deaths occur in China .As a potentially curative treatment for **liver** cirrhosis and **cancer**, **liver transplantation** (LT) is widely ...

Cited by: 1 **Author:** Zhe Yang, Shuo Wang, Xin-Yao Tian, Qin...

Publish Year: 2020

Locoregional Therapy and Recurrent Hepatocellular ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777313>

Kaplan-Meier analysis of **hepatocellular carcinoma** (HCC) **recurrence after** orthotopic **liver transplantation**. (A) The survival rate was significantly decreased in **patients** with HCC **recurrence**. (B–F) **Recurrence** risks were stratified by locoregional therapies and tumor necrosis. Log Rank Test, $p < 0.05$ was considered as significant.

Cited by: 11 **Author:** Min Xu, MB Majella Doyle, Babak Banan,...

Publish Year: 2017

Systemic therapies for hepatocellular carcinoma: a recap ...

<https://hrjournal.net/article/view/2501> ▾

Lenvatinib versus sorafenib in **first-line** treatment of **patients** with unresectable **hepatocellular carcinoma**: a randomised phase III non-inferiority trial. Lancet 2018;391:1163-73. DOI; 56. Markowitz JN, Fancher KM. Cabozantinib: a multitargeted oral tyrosine kinase inhibitor. Pharmacotherapy 2018;38:357-69. DOI PubMed; 57.

Author: Petros Giovanis, Manuela De Bona, F... **Publish Year:** 2018